SCHEMBL1627752

SCHEMBL1627752

CCOC(=O)C1=C(O)c2cc(F)c(F)cc2C2(CCOCC2)C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 1/20 0.48
ALDH1A1 P00352 6/20 0.34
KDM4E B2RXH2 5/20 0.34
HPGD P15428 4/20 0.34
HSD17B10 Q99714 2/20 0.34
NPSR1 Q6W5P4 6/20 0.33
MAPT P10636 5/20 0.32
MEN1 O00255 4/20 0.32
LMNA P02545 4/20 0.32
KMT2A Q03164 4/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
PKM P14618 2/20 0.32
ATM Q13315 2/20 0.32
L3MBTL1 Q9Y468 3/20 0.32
ALOX12 P18054 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
MCL1 Q07820 1/20 0.32
CCR6 P51684 1/20 0.32
HKDC1 Q2TB90 1/20 0.32
KDM4C Q9H3R0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1628183 0.92 SPR (0.49) SPRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1625313 0.87 SPR (0.46) SPRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1625662 0.87 SPR (0.53) SPRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1626606 0.87 SPR (0.52) SPRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1625317 0.83 SPR (0.47) SPRALDH1A1KDM4EHSD17B10NPSR1
SCHEMBL1627845 0.83 SPR (0.68) SPRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1627764 0.83 SPR (0.58) SPRALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1626733 0.82 SPR (0.44) SPRKDM4ENPSR1MAPTMEN1
SCHEMBL1627155 0.82 SPR (0.49) SPRALDH1A1KDM4EHPGDNPSR1
SCHEMBL1625808 0.82 SPR (0.55) SPRALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 US disclosed
EP-2111399-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF Amgen Inc. (US) 2009-10-28 EP disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed
WO-2008076427-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN SPR 754/4885ALDH1A1 128/4885KDM4E 977/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN SPR 754/4885ALDH1A1 128/4885KDM4E 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.